Emend (Fosaprepitant) and QT prolongation
Result of checking the interaction of drug Emend (Fosaprepitant) and disease QT prolongation for safety when used together.
When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.
Consumer:Fosaprepitant, a prodrug of aprepitant, is a weak inhibitor of CYP3A4, and aprepitant is a substrate, inhibitor, and inducer of CYP3A4. An increased plasma concentration of fosaprepitant could cause QT prolongation. Caution is advised in patients with long QT, and in patients receiving other drugs that are CYP3A4 substrates as it may result in a risk of higher plasma concentrations and adverse events. Close monitoring is recommended in these patients.
Generic Name: fosaprepitant
Brand Name: Emend for Injection
Synonyms: Fosaprepitant